Search Results

Home → Flash News → Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Published on June 3, 2025 Category Dr. GPCR Podcast Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Previous Next Recent Articles

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Complimentary Lunch < Previous Session Next Session >

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Gunnar Schulte About Dr. Gunnar Schulte Gunnar Schulte is a Professor in receptor pharmacology and research group leader for the section Receptor Biology and Signaling at the Department of Physiology and Pharmacology. He has a background in biochemistry from the Free University in Berlin/Germany and a Ph.D. in molecular pharmacology (supervisor: Bertil B Fredholm; 1998-2002) from Karolinska Institutet. As a postdoc, he trained first with Ernest Arenas (Karolinska Institutet, Molecular Neurobiology; 2003-2005) and later with Roger J Summers (Monash University, Melbourne Australia, GPCR pharmacology; 2006) before starting his independent research team "Receptor Biology & Signalling" in 2008. Gunnar Schulte is also the scientific secretary of the Swedish Society for Medical Research (SSMF) and a member of the editorial board/editorial advisory board of Molecular Pharmacology, British Journal of Pharmacology, Pharmacological Reviews, and The Journal of Biological Chemistry. General Research Interest: The focus in the Schulte lab is on Frizzled signaling and pharmacology aiming to understand the role of WNT/Frizzled signaling in biology, physiology, and disease. Most importantly my research team tries to understand underlying mechanisms of WNT-receptor interaction, the relevance of receptor dynamics, and receptor complex composition for signal initiation and specification. The ultimate aim is to use the new knowledge to find, create and optimize Frizzled-targeting small molecule drugs to improve future therapies of human disease. Dr. Gunnar Schulte on the web Schulte Lab LinkedIn Google Scholar Orcid YouTube Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Translating computational approaches to GPCR biologists with Dr. Riccardo Capelli About Dr. Riccardo Capelli Dr. Riccardo Capelli is an assistant professor in Applied Physics at the Department of Biosciences, University of Milan. He earned his PhD in Physics at the same university, focusing on in silico structural vaccinology and advancing free energy calculation techniques. He then held a postdoctoral position at Forschungszentrum Jülich (Germany), where he worked on calculating ligand binding kinetics using classical molecular dynamics. This was followed by a postdoctoral role at the Polytechnic University of Turin (Italy), where he developed coarse-grained models for self-assembling systems. Now in a tenure-track position, his research spans the development of computational methods such as structure-based models and enhanced sampling techniques, as well as their application to biomolecular systems, mainly on GPCRs activation and dynamics. Dr. Ricardo Capelli on the web Google Scholar ResearchGate Bysky App : @ riccardocapelli.bsky.social Twitter X : @ ric_capelli Computational Structural Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Michael Feigin About Dr. Michael Feigin "Dr. Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo, NY. He earned his Ph.D. under Dr. Craig Malbon at SUNY Stony Brook studying the role of G-protein coupled receptors (GPCRs) and their regulators in the Wnt signaling pathway. Mike then joined the lab of Dr. Senthil Muthuswamy at Cold Spring Harbor Laboratory and probed the roles of polarity proteins (Feigin, et al., Cancer Research, 2014) and GPCRs (Feigin, et al., PNAS, 2014) in breast cancer pathogenesis, using mouse models, three-dimensional cell culture and computational approaches to drug target discovery. When Dr. Muthuswamy moved to the University of Toronto, Mike joined the laboratory of Dr. David Tuveson at CSHL where he participated in the development of an organoid system for the culture of normal and malignant pancreatic tissue, allowing advances in sequencing, target discovery and biomarker development. He also continued his interest in computational analysis of cancer drivers by co-developing GECCO, an algorithm for the identification of noncoding mutations driving gene expression in pancreatic cancer (Feigin and Garvin, et al., Nature Genetics, 2017). Mike's lab has two main areas of interest: 1) alternative polyadenylation as a targetable driver of pancreatic cancer, and 2) dysregulation of the pancreatic tumor microenvironment by commonly prescribed anti-anxiety drugs." Dr. Michael Feigin on the web Roswell Park Feigin Lab Google Scholar LinkedIn Twitter Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick recap Yamina and Mike engaged in a conversation about their scientific research experiences. Mike shared his journey from his Ph.D. struggles to his current role as a professor, emphasizing the importance of resilience and creativity. They also discussed his research on cell polarity and its role in cancer progression, his work on G-protein coupled receptors (GPCRs) in breast cancer, and his interest in pancreatic cancer. The discussion also covered the challenges they face in studying GPCRs due to their low expression levels and the difficulty of localizing these receptors in tissues. Next steps • Mike will consider using Twitter to post job positions in his lab. Summary Science Roles and Resilience Yamina and Mike had a conversation about their roles and experiences in the field of science. Yamina introduced herself and Mike shared his educational background and his journey to becoming a professor. Mike also spoke about his initial struggles during his Ph.D., such as a difficult model system and a lack of experimental results. He explained that he overcame these challenges by reading extensively and contemplating alternative plans. The conversation also highlighted the importance of resilience and creativity in scientific research. Science Journey and Postdoc Decision Mike discussed his journey into science and his decision to pursue a postdoc at Cold Spring Harbor. He shared that his interest in science originated from a young age and his desire to gain more knowledge about cancer biology led him to transition into using mouse models. Yamina asked about his move from in vitro to in vivo work, and Mike explained that he wanted to use better models to understand cancer signaling pathways. They also shared their personal experiences and interest in the field of biology. Towards the end, Mike mentioned that he stayed at Cold Spring Harbor even after his mentor left for Toronto. Mike's Research on Cell Polarity and GPCRs in Cancer Mike shared his research on cell polarity and its role in cancer progression, particularly focusing on the potential of disrupted cell polarity as a driver of tumorigenesis. He also discussed his work on G-protein coupled receptors (GPCRs) in breast cancer, identifying GPR161 as a potential drug target due to its high expression in triple negative breast cancer. Mike then transitioned to pancreatic cancer, questioning why genes are dysregulated in cancer, which led him to explore different aspects of gene regulation and its relation to cancer progression. Yamina acknowledged the difficulty in identifying GPCRs expressed in cancer cells but not in normal ones, and commended Mike's innovative approach to the question. Career Trajectory and Faculty Position Yamina and Mike discussed Mike's career trajectory and his decision to pursue a faculty position. Mike expressed his initial reluctance due to a lack of confidence and fear of not being ready. However, he decided to undertake another postdoc to gain more experience and confidence. He also highlighted the importance of publishing strong papers and having a clear vision for his lab. Yamina emphasized the importance of thorough preparation and planning before applying for faculty positions. They also discussed the challenges of the two-body problem, where both partners need to find suitable positions. Mike shared his strategy of developing preliminary projects and gathering data to strengthen his application. Teamwork and Flexibility in Scientific Research Mike shared about his recent promotion and the way he has managed his team, encouraging them to come up with their own ideas and then guiding them. Yamina congratulated Mike on his promotion and discussed the importance of flexibility in scientific research, even when starting with a clear plan. Mike also mentioned how his team collaborates closely, with weekly roundtable discussions where everyone shares their progress and issues. The conversation ended with Yamina expressing interest in learning more about Mike's two main research areas in his lab. GPCR Targeted Drugs and Gene Regulation in Cancer Cells Mike presented research on the effect of GPCR-targeted drugs on cancer-associated fibroblasts and discussed their work on gene regulation in fibroblasts. He highlighted their interest in non-coding mutations in promoters and the 3'UTR region important for gene regulation. Mike also shared about a drug that targets an enzyme involved in mRNA cleaving, which has been found to stop cancer cells from growing and invading. He also discussed the impact of disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic index for a drug called JTE-6.7. Yamina asked about the typical role of the enzyme and the challenges in delivering a molecule to target this enzyme and only cancer cells. Cytokine Inhibition, Collaboration, and Anti-Anxiety Drug Research Mike discussed the ongoing research on a drug that inhibits cytokine synthesis, its potential in killing cancer cells, and the team's efforts to understand its resistance mechanisms. He also touched upon a collaboration with Todd Ricky's group at UPenn to explore the GPCR side of the lab, which led to the discovery of potential tumor suppressors and oncogenes in melanoma. Furthermore, Mike mentioned a qualifying exam where students proposed new projects, highlighting Abby Cornwell's project on the effects of anti-anxiety drugs on pancreatic cancer patients, and the team's research on the potential issues with certain anti-anxiety drugs. The team found that these drugs could interact with GPR68, which is highly expressed in cancer-associated fibroblasts and is crucial for their function, leading to complications in cancer patients. The team is now examining other anti-anxiety drugs and common patient medications in the context of pancreatic cancer. GPCRs and Cancer Immune Modulation Yamina and Mike had a discussion about their research on GPCRs, specifically focusing on GPR68 and its role in the tumor microenvironment. They also touched upon the potential of GPCR modulation in stimulating the immune system to fight cancer. Mike shared his team's current focus on alprazolam, an anti-anxiety medication that has unexpected effects in the tumor microenvironment. They also discussed the challenges they face in studying GPCRs due to their low expression levels and the difficulty of localizing these receptors in tissues. Mike expressed a need for better tools to study GPCR localization in tissues. Scientific Journey and Drug Discovery Challenges Mike shared significant moments in his scientific journey, including the discovery of RGS proteins and its impact on his research approach. He also discussed his experiments and discoveries about GPR161 in mammary epithelial cells, the effect of alprazolam on tumors, and the potential dangers of drug interactions. Yamina proposed further exploration of dosage and length of treatment in a mouse model and suggested using a biosensor-based assay to examine dose-response curves. The conversation highlighted the complexities and challenges of drug prescription and the potential for alternative treatments. Science Journeys and Career Advice Yamina and Mike discussed their experiences in the field of science. Mike advised junior scientists to focus on projects they are passionate about, emphasizing that ownership and full investment in a project can make dealing with challenges easier. Yamina shared her personal journey, describing how she took her project in a different direction and felt a sense of ownership. Mike reflected on his early years as a postdoc, admitting that he lacked focus and didn't see the direct impact of his work on patients. He highlighted the importance of re-evaluating one's work and its potential implications. Towards the end, Yamina asked about job opportunities in Mike's lab, to which Mike responded that potential candidates can find him on Twitter. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Can models predict drug outcomes? Jens Carlsson shares how GPCR modeling is moving from explanation to real prediction in drug discovery. << Back to podcast list Dr. GPCR Podcast Strategic Partners Model. Predict. Discover. with Dr. Jens Carlsson What if models didn’t just explain the past — but could truly predict what comes next? In this episode, Dr. Jens Carlsson reveals how computational modeling is evolving from explanation to real prediction—and how that shift accelerates real-world discovery. Dr. Jens Carlsson, Professor of Computational Biochemistry at Uppsala University, joins Dr. Yamina Berchiche to share his unconventional journey from aspiring engineer to GPCR modeler. With a deep focus on structure-based drug design, Jens discusses how his lab bridges simulation and experiment—and why understanding the limits of prediction is just as critical as the predictions themselves. From virtual screening of billions of molecules to leveraging AlphaFold for structure prediction, Jens shares the cutting-edge tools his lab uses—and the collaborative mindset required to turn models into testable hypotheses. Along the way, he reflects on key career moments, the role of mentorship, and how curiosity continues to drive his work across both academic and industry settings. Why This Matters Computational models are moving beyond interpretation into real-world prediction of ligand-receptor interactions. Bridging computation, chemistry, and pharmacology is key to speeding up drug discovery. AI and machine learning are opening new doors—but only if scientists know their tools’ limits. What You’ll Learn Why Jens Carlsson believes modeling should predict , not just explain How his team uses structure-based modeling to identify novel GPCR ligands The value of failure—and how it shaped his path as a scientist Why collaborations between modelers and experimentalists are more vital than ever How AlphaFold is shaking up structural biology—and where it still falls short Advice for junior scientists: what really matters when building a research career Who Should Listen GPCR scientists and pharmacologists Computational chemists and structural biologists Early-career researchers exploring drug discovery Biotech leaders and R&D strategists Anyone interested in predictive modeling, AI in biology, or structure-function relationships About Jens Carlsson Jens Carlsson is a Professor of Computational Biochemistry at Uppsala University, where his research group uses structure-based modeling to investigate GPCRs. His team focuses on understanding how ligands modulate receptor function and how those insights can drive drug discovery. By combining molecular docking, molecular dynamics, and machine learning, Jens works at the intersection of computation and pharmacology, often in close collaboration with experimental labs. Trained initially as a biotechnology engineer, Jens discovered his true calling during an internship where his modeling skills stood out, mainly because his bench skills didn’t. That moment launched a career built around using computational tools to answer big biological questions. His journey took him from Sweden to Scripps Research and UCSF, where he was first introduced to GPCRs and mentored by pioneers like Brian Shoichet and Ken Jacobson. Jens is passionate about prediction over explanation: building models that can guide experiments, not just interpret them. Outside academia, he advises companies through a consulting arm focused on ligand design strategy. With a reputation for collaborative science, Jens is a strong advocate for bringing together chemists, modelers, and biologists to accelerate discovery and train the next generation of GPCR researchers. Jens Carlsson on the web Carlsson Group Uppsala University LinkedIn Hit play now to hear how prediction is reshaping GPCR science, and what that means for the future of drug discovery. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization reframed her view of receptor pharmacology. Home → Flash News → where signaling happens inside a cell Why does it matter where signaling happens inside a cell? Published on November 13, 2025 Category Dr.GPCR Podcast Why does it matter where signaling happens inside a cell? This moment cuts straight to the heart of how many of us fell in love with GPCR biology — that realization that signaling isn’t random. It’s structured, organized, and spatially constrained. Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization reframed her view of receptor pharmacology. This shift — from thinking about “pathways” to understanding localized signaling architecture — is what drove her to build a research career around spatial control of GPCR signaling. This isn’t just academic. The way signals are organized defines specificity, drug response, and potential for targeted therapies. If you work with GPCRs, this perspective changes how you design experiments and interpret data. 🎧 Watch this insight — or listen to the full conversation with Michelle.🔗 Full episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling ✨ Join Premium: https://www.ecosystem.drgpcr.com/gpcr-university-pricing #GPCR #DrGPCR Previous Next Recent Articles

Home → Flash News → From aspiring doctor to GPCR scientist! 🔬In this episode, Ian Chronis shares his journey from med school dreams to a PhD in pharmacology, diving into the fascinating world of receptor signaling. Can you guess what’s his favorite GPCR? ✅ Hear his response: Ep 164 with Dr. Ian Chronis #SciencePodcast #GPCR #PhDLife #DrGPCR Published on April 17, 2025 Category Dr. GPCR Podcast From aspiring doctor to GPCR scientist! 🔬In this episode, Ian Chronis shares his journey from med school dreams to a PhD in pharmacology, diving into the fascinating world of receptor signaling. Can you guess what’s his favorite GPCR? ✅ Hear his response: Ep 164 with Dr. Ian Chronis #SciencePodcast #GPCR #PhDLife #DrGPCR Previous Next Recent Articles

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Stephane Angers About Dr. Stephane Angers Dr. Angers is an expert in the field of signal transduction. He obtained his Ph.D. from the Université de Montréal in 2002 under the guidance of Dr. Michel Bouvier . His thesis work led to the development and application of light energy transfer methodology to study protein-protein interaction and signal transduction. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle under Dr. Randall T. Moon , where he identified and characterized novel components of the Wnt signaling pathway and a new class of E3 ubiquitin ligases . In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and the Department of Biochemistry at the University of Toronto. He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signaling mechanisms in development, adult tissue homeostasis, and human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics , which are pursuing the clinical development of these molecules. In September 2021, Dr. Angers was named Director of the Donnelly Centre of Cellular and Biomolecular Research at the University of Toronto, an internationally recognized Research Institute bringing together multidisciplinary teams of scientists. Dr. Stephane Angers on the web Angers Lab The Donnelly Centre Twitter Dr. GPCR Ecosystem LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Nariman Balenga About Dr. Nariman Balenga "I received my Master’s degree from the University of Tehran, Iran, in 2005 by studying the suitability of nanoparticles as porters of DNA vaccination against allergens in mice. Then I pursued my education in the lab of Dr. Maria Waldhoer at the Medical University of Graz, Austria, and received my Ph.D. in Molecular Medicine in 2010 after studying the orphan atypical cannabinoid receptor, GPR55 and its crosstalk with CB1R and CB2R in endothelial cells and neutrophils. I followed my interest in allergy and GPCRs by joining the lab of Dr. Kirk Druey at NIAID/NIH, where I characterized the role of RGS4 and RGS5 in airway hyperresponsiveness and lung fibrosis in acute and chronic mouse models of allergic asthma. I was fascinated by the multitude of processes that are regulated/dysregulated by GPCRs and RGS proteins in the lungs of patients with asthma. At the height of curiosity, a seemingly naïve idea at the dinner table led to a side project by which I characterized the impact of a fungal allergenic source on the function of airway smooth muscle cells. A fungal serine protease allergen with GPCR-modulating features was discovered as a new biomarker and target in patients with severe asthma. In 2015 I joined the University of Maryland School of Medicine as an Assistant Professor. I studied the function of RGS5, calcium-sensing receptor, and an orphan adhesion GPCR, GPR64/ADGRG2 in parathyroid glands of patients with hyperparathyroidism and their impact on body calcium homeostasis and bone resorption in relevant transgenic mice. In 2021, I joined the Ferring Research Institute of Ferring Pharmaceuticals in San Diego as a scientist." Dr. Nariman Balenga on the web Researchgate Linkedin.com Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Richard Premont About Dr. Richard Premont "Dr. Premont obtained his B.S. in Biology and Chemistry at the California Institute of Technology in 1985, and M.Ph . and Ph.D. in Biomedical Sciences (Pharmacology) at Mount Sinai School of Medicine (City University of New York) in 1990 and 1992, working with Ravi Iyengar on regulation/desensitization of the liver glucagon receptor and glucagon-stimulated adenylyl cyclase system. In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert Lefkowitz and Marc Caron at Duke University. His initial project to identify and clone taste receptors was unsuccessful, but led to the identification of GRK5 and continued focus on GRKs (particularly GRKs 4,5,6) and arrestins as GPCR regulators and as mediators of distinct signaling pathways through partners including GIT1. In 1999, obtained an independent faculty position at Duke in Gastroenterology, where he remained until 2018 studying GPCRs and their signaling pathways in the liver and in liver disease. In 2018, he moved to Harrington Discovery Institute and Case Western Reserve University, where he studies GPCR regulation by S-nitrosylation. My research focus is on understanding how distinct cellular signaling pathways interact and are coordinated to produce integrated physiological responses, and how dysregulation of this coordination results in pathophysiology. For this, we have worked in three main areas: the regulation of G protein-coupled receptor signaling particularly by the G protein-coupled receptor kinase (GRK) – beta-arrestin system, the coordination of heterotrimeric G protein, small GTP-binding protein and protein kinase pathways by GIT/PIX scaffolding complexes during cellular signaling, and characterizing the role of protein S-nitrosylation as a signaling post-translational modification in mediating and regulating cellular signaling pathways, particularly in conjunction with better characterized signaling systems. In our work, we utilize methods including structural biology and proteomics, molecular biology and biochemical enzymology, primary and model cell culture, and transgenic, knockout, knock-in and conditional models of mouse physiology and behavior." Dr. Richard Premont on the web Google Scholar LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

< Back This is a Title 01 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. You can create as many collections as you need. Your collection is already set up for you with fields and content. Add your own, or import content from a CSV file. Add fields for any type of content you want to display, such as rich text, images, videos and more. You can also collect and store information from your site visitors using input elements like custom forms and fields. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Preview your site to check that all your elements are displaying content from the right collection fields. Previous Next News Get in Touch Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About

Home → Flash News → 🚀 Science and finance aren't opposites—they’re partners. In this Ep.165 of the Dr.GPCR Podcast, Joe St. Germain & Chuck DeWeese reveal what it really takes to build sustainable startups and nonprofits behind the scenes. Grant accounting, character-first hiring, mission-driven growth—it’s all here! 🎧 Listen now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Published on April 29, 2025 Category Dr. GPCR Podcast 🚀 Science and finance aren't opposites—they’re partners. In this Ep.165 of the Dr.GPCR Podcast, Joe St. Germain & Chuck DeWeese reveal what it really takes to build sustainable startups and nonprofits behind the scenes. Grant accounting, character-first hiring, mission-driven growth—it’s all here! 🎧 Listen now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Previous Next Recent Articles

Home → Flash News → Dr. GPCR University is officially back! 🎆 Join Dr. Terry Kenakin for "The Practical Assessment of Signaling Bias" workshop! 🚀 Learn the practical issues with detecting, measuring, and quantifying GPCR ligand-biased signaling. ✳️Early Bird discounts for Premium Members! ➡️Register today at https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on January 20, 2025 Category GPCR University Dr. GPCR University is officially back! 🎆 Join Dr. Terry Kenakin for "The Practical Assessment of Signaling Bias" workshop! 🚀 Learn the practical issues with detecting, measuring, and quantifying GPCR ligand-biased signaling. ✳️Early Bird discounts for Premium Members! ➡️Register today at https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → Ben Clements reveals a 10x improvement in efficacy using GPCR-targeted PAMs, in Ep.166 of the Dr.GPCR Podcast,. The catch? It’s all about understanding the system, not replacing it. From neuromas to novel modulators, this episode is full of breakthroughs that matter for patients. 📲 Watch now: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Published on May 22, 2025 Category Dr. GPCR Podcast Ben Clements reveals a 10x improvement in efficacy using GPCR-targeted PAMs, in Ep.166 of the Dr.GPCR Podcast,. The catch? It’s all about understanding the system, not replacing it. From neuromas to novel modulators, this episode is full of breakthroughs that matter for patients. 📲 Watch now: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Previous Next Recent Articles

Dr. Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights. Home → Flash News → How sensitive can a GPCR really be How sensitive can a GPCR really be? Published on November 9, 2025 Category Dr. GPCR Podcast Think femtomolar. That’s the scale we’re talking about. This week on the Dr. GPCR Podcast , we sit down with Michelle Halls , leader of the Spatial Organisation of Signalling lab at Monash University. Her team is redefining how we understand GPCR signaling — not just at the cell surface, but in space, time, and disease context. In this episode, you’ll learn: How GPCR pre-assembly enables femto-level signal detection. Why receptor location matters as much as receptor type. How disease can hijack signaling organization — and what that means for drug discovery. Michelle’s work bridges elegant mechanistic biology with translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic precision. 🔗 Listen here → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling 🎓 Explore Dr. GPCR Premium → https://www.ecosystem.drgpcr.com/gpcr-university #GPCR #DrGPCR #pharmacology #drugdiscovery #receptors #biotech #signaltransduction Previous Next Recent Articles

Home → Flash News → ⚠️Registration Deadline today! This is your last chance to register for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin. Learn theoretical background for the techniques and apply with hands-on exercises 💪 ✳️Last chance!!! https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on February 14, 2025 Category Dr. GPCR Courses ⚠️ Registration Deadline today! This is your last chance to register for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin. Learn theoretical background for the techniques and apply with hands-on exercises 💪 ✳️ Last chance!!! https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Previous Next Recent Articles

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Breakfast 2 Date & Time Saturday, November 4th / 7:30 AM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Trainee Symposium II Date & Time Thursday, November 2nd / 3:00 PM - 4:00 PM Title: Linking Proteinase Activated Receptor (PAR) Cleavage to Osteoarthritis (OA) Severity About Amr Mousa "I am currently a Ph.D. student at the Schulich School of Medicine and Dentistry, Western University, researching the molecular mechanisms of Proteinase-Activated Receptors (PARs) in osteoarthritis. I got my Bachelor's in Pharmacy from Minia University in 2011 and began my career as a teaching and research assistant in Pharmacology and Toxicology. Later, I completed my Master's degree in Pharmacology at Minia University, focusing on hydrogen sulfide's role in hypertension-induced endothelial dysfunction. In November 2021, I joined Dr. Ramachandran's lab as a visiting graduate student, and in September 2022, I enrolled in the direct-entry Physiology and Pharmacology Ph.D. program with a specialization in musculoskeletal health research (CMHR). During my short academic journey, I was awarded the Young Investigator Transdisciplinary Research Award (2022-2023 and 2023-2024) from the bone and joint institute, Western University and the New Student Poster Award (2022). I also received the Scientific Excellence and Publication Award from Minia University for the years 2022 and 2023." Amr Mousa on the web Google Scholar Dr. GPCR Title: Balancing G Protein Selectivity and Efficacy in the Adenosine A2A Receptor About Louis-Philippe Picard "I earned my Ph.D. in Biochemistry, working under the guidance of Dr. Michel Bouvier, at the University of Montreal from 2015 to 2019. Currently, I am engaged in postdoctoral research in the laboratory of Dr. Scott Prosser. My primary research focus lies in gaining deeper insights into the structural mechanisms governing G protein-coupled receptors (GPCRs) and G protein activation. I employ a multidisciplinary approach that combines molecular pharmacology, biochemical assays, and biophysical techniques to unravel the intricacies of these processes." Louis-Philippe Picard on the web Google Scholar Dr. GPCR Title: Development of a Transgenic Mouse Platform for the Detection of Endogenous G protein Activity About Remi Janicot "After graduating as an undergrad from Ursinus College, I joined the Johns Hopkins School of Medicine to work as a lab tech in a neurophysiology lab investigating mechanisms behind pediatric epilepsy disorders. I then joined Boston University to pursue my scientific career as PhD student and joined the lab of Dr. Mikel Garcia-Marcos which investigates GPCR and G protein signaling" Remi Janicot on the web Boston University Dr. GPCR Title: Antibodies Expand the Scope of Angiotensin Receptor Pharmacology About Meredith Skiba "Meredith completed her PhD in Biological Chemistry with Janet Smith at the University of Michigan studying the biosynthesis of polyketide natural products using x-ray crystallography. She then joined Andrew Kruse’s lab for her postdoc in 2018 where she has employed protein engineering, receptor pharmacology, and structural biology to study how different types of ligands modulate angiotensin receptor signaling." Meredith Skiba on the web Harvard University University of Michigan Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Poster Session #2 Date & Time Friday, November 3rd / 5:00 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Home → Flash News → This study adds a key piece to the puzzle of adhesion GPCR signaling. Understanding receptor-specific nuances, like the role of NTF cleavage, is crucial for decoding their functional outcomes. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️https://www.ecosystem.drgpcr.com/adhesion-gpcrs/n-terminal-fragment-shedding-contributes-to-signaling-of-the-full-length-adhesion-receptor-adgrl3 #gpcr #drgpcr Published on January 28, 2025 Category GPCR Weekly News This study adds a key piece to the puzzle of adhesion GPCR signaling. Understanding receptor-specific nuances, like the role of NTF cleavage, is crucial for decoding their functional outcomes. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️ https:// www.ecosystem.drgpcr.com/adhesion-gpcrs/n-terminal-fragment-shedding-contributes-to-signaling-of-the-full-length-adhesion-receptor-adgrl3 #gpcr #drgpcr Previous Next Recent Articles

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Board meeting/General assembly Welcome to Join Coming Soon < Previous Session Next Session >

Applying Pharmacology to Drug Discovery Dr. Terry Kenakin Get Started Premium Members benefits: - Subscribe and save 25% on every GPCR Course - Early-bird access - Recordings will be available < Back to GPCR courses Watch recording Your Instructor Dr. Terry Kenakin

Home → Flash News → insights into g protein coupling preference from cryo em structures of gq bound PTH1R Published on July 14, 2025 Category GPCR Weekly News What drives Gq vs. Gs selectivity at PTH1R? This new Nature Chemical Biology paper reveals cryo-EM structures of Gq-bound PTH1R—highlighting how N-linked glycans and ICL2 interactions stabilize receptor conformations that favor Gq coupling. ♦️ Two distinct Gq-bound conformations ♦️ Comparison with Gs-bound PTH1R ♦️ Strategic implications for biased agonist design A critical advance for anyone working on class B1 GPCRs, bone biology, or biased signaling. ➡️ Read the paper: https://www.nature.com/articles/s41589-025-01957-6?utm_content=buffer3b1fa&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer #DrGPCR #GPCR #PTH1R #BiasedAgonism #CryoEM #Pharmacology #Osteoporosis #DrugDiscovery Previous Next Recent Articles

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. GPCR Team About Dr. Yamina Berchiche Dr. Yamina A. Berchiche is the founder of Dr. GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug targets. The mission of Dr. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the field and providing exposure to scientists through the Dr. GPCR podcast. Dr. Berchiche obtained her Master’s and Ph.D. in Biochemistry at the University of Montreal in Canada before training at Rockefeller University in New York and the National Institutes of Health in Bethesda, Maryland. She developed expertise over the past two decades studying structure/function relationships of GPCRs using live-cell bioluminescence resonance energy transfer (BRET). Her work focused on chemokine receptors, members of the GPCR family that control cell movement in the body. Dr. Yamina Berchiche on the web Website LinkedIn Facebook Twitter ResearchGate PubMed Google Scholar Dr. GPCR About Dr. Shivani Sachdev Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health. Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain. She received her undergraduate degree in Biotechnology from KIIT University in India. She subsequently joined Professor Mark Connor's laboratory at Macquarie University in Australia. Dr. Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid receptors. She is also very active within the pharmacology community and currently serves on the editorial board of the British Journal of Pharmacology. Given her expertise in GPCR pharmacology and scientific communication, she is poised to make valuable contributions to the field and expand our understanding of GPCR signaling. Dr. Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr. GPCR About Dr. Inês Pinheiro PharmD by training and Ph.D. candidate in Hartley's lab at the University of Geneva. As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and immuno-oncology. Dr. Inês Pinheiro on the web LinkedIn University of Geneva Twitter Dr. GPCR About Dr. Monserrat Avila Zozaya I did a PhD in cell biology at CINVESTAV, Mexico. During that time, I investigated the effect of lung cancer-related mutations in the GAIN domain of the Latrophilin 3 receptor. My long-term interest is focused on understanding the mechanisms mediated by GPCRs at the cellular communication level. Dr. Monserrat Avila Zozaya on the web LinkedIn Antony Boucard Lab Dr. GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery Biology and Pharmacology from Monash University. Currently serving as a Post Doctoral research fellow at Monash University, John plays a pivotal role in the pharmacological screening of compounds for a commercial drug discovery program. With prior industry experience as a Clinical Research Associate at IQVIA and regulatory officer at the Food and Drug Authority (FDA) in Ghana, John has a proven track record of ensuring compliance with protocols and regulatory standards. Driven by a passion for advancing drug development, John is committed to leveraging his expertise to enhance healthcare outcomes and contribute to the growth of the pharmaceutical and biotech industry. John Azietaku on the web LinkedIn Dr. GPCR About Ya-Tzu Li Ya-Tzu is a Master's student at the University of South Florida, utilizing large-scale virtual drug screening to identify agonists and antagonists targeting Class A GPCRs. Since beginning her undergraduate studies, she has used computational methods like molecular dynamics simulations and free energy landscape analysis to understand the signaling pathways and activation mechanisms of the Dopamine D3 receptor and the CXCR4-CXCL12 complex. In August, Ya-Tzu will continue her academic and research pursuits by beginning her PhD training in Medical Science at USF, aiming to further contribute to the field of medical pharmacology. Ya-Tzu Li on the web LinkedIn Dr. GPCR About Cam Sinh Lu Cam Sinh Lu is a PhD student at Monash Institute of Pharmaceutical Sciences, Monash University, with a deep interest in understanding drug-receptor interactions. With an immense passion for molecular pharmacology, his research focuses on elucidating the molecular basis of membrane protein signalling using quantitative assays and molecular modelling. Further down the track, he aims to apply this knowledge to develop novel chemical treatments for neuronal and cardiovascular diseases. Cam Sinh Lu on the web LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → In case you haven’t heard, our next Dr.GPCR University course is open for registrations 🙂 Learn about "The Practical Assessment of Signaling Bias" with Dr. Terry Kenakin. 🙌 Hands-on exercises included! ✳️Only 25 spots available ➡️Enjoy a 25% discount with your Premium Membership https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on January 24, 2025 Category GPCR University In case you haven’t heard, our next Dr.GPCR University course is open for registrations 🙂 Learn about "The Practical Assessment of Signaling Bias" with Dr. Terry Kenakin. 🙌 Hands-on exercises included! ✳️Only 25 spots available ➡️Enjoy a 25% discount with your Premium Membership https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Previous Next Recent Articles

Learn why some inhibitors act long after dosing ends. Explore the kinetic principles behind persistent binding and smarter drug design. Home → Flash News → irreversible drugs post 2 Persistent binding ≠ just covalent. Published on October 24, 2025 Category Terry's Corner Why do some inhibitors act long after the drug itself is gone? It’s not always about covalent chemistry — often, it’s about kinetics. Irreversible interactions emerge when one simple imbalance tips the scale: inflow outpacing outflow. That’s why a compound like phenoxybenzamine can knock down receptor populations after just a brief exposure. And why slow-dissociating allosteric inhibitors can reshape signaling curves for hours — or even days — after dosing stops. When persistent binding meets structured tissues, this effect can amplify or collapse. High-affinity molecules can get trapped at the periphery of a tumor, never reaching the core. The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure. This isn’t a subtle nuance. Binding kinetics are a design variable, as critical as potency or clearance. Get it wrong, and the best molecule on paper stalls in development. Get it right, and you unlock durable efficacy with leaner dosing strategies. If your discovery strategy still treats kinetics as an afterthought, you’re already behind. ✳️ Read More: https://www.ecosystem.drgpcr.com/post/beyond-clearance-the-strategic-power-of-irreversible-drug-binding #GPCR #DrGPCR #Pharmacology #DrugDiscovery #BindingKinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDesign Previous Next Recent Articles

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session VIII * Physiological and pathological roles of AGPCRs in the periphery The CELSR/ADGRC Homolog Flamingo Is Not Autoproteolytically Processed By The GAIN Domain Tobias Langenhan Characterization of Phenotypes Associated with GPR110 Deletion Hee-Yong Kim The Adhesion GPCR Cupidon Regulates Mating In The Closest Relatives Of Animals Alain Garcia De Las Bayonas Critical role for CD97/ADGRE5 in the induction of allergic airway inflammation Gabriela Aust The CELSR/ADGRC Homolog Flamingo Is Not Autoproteolytically Processed By The GAIN Domain Tobias Langenhan Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Tobias Langenhan, Nicole Scholz, Genevieve M. Auger, Helen Strutt, David Strutt" About Tobias Langenhan "1997-2004: Medical school and Dr. med. Neuroanatomy (Würzburg, Germany); 2004-2005: M.Sc. Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany); 2016: Heisenberg professorship (Würzburg, Germany); 2016-to date: Professor and Chair in Biochemistry (Leipzig, Germany)" Tobias Langenhan on the web Langenhan Lab LinkedIn Characterization of Phenotypes Associated with GPR110 Deletion Hee-Yong Kim Abstract "G-protein coupled receptor 110 (ADGRF1, GPR110), an adhesion GPCR recently deorphanized, plays an important role in in the development of neurons and cognitive function. Synaptamide, an endogenous ligand for GPR110, binds to the N-terminal G-protein autoproteolysis-inducing (GAIN) domain of GPR110, and activates GPR110/cAMP signaling. This activation promotes neurogenic differentiation of neural stem cells, neurite growth, and synaptogenesis of developing neurons. In addition, a significant role of GPR110 in blood brain barrier (BBB) function has been discovered. GPR110 is highly expressed in mouse and human NPCs and neurons, while its expression was absent in astrocytes. GPR110 is also highly expressed in the kidney, however, little is known about the function of this receptor in renal physiology. To extend our understanding of the role of GPR110 signaling in kidney, we evaluated the urine albumin level in mice devoid of GPR110 gene (GPR110 KO) compared to the wild type (WT). To provide the molecular basis for the renal phenotype, we analyzed in parallel differential expression of kidney proteins in GPR110 KO and WT mice by label-free LC-MS/MS and pathway analysis. We found that the albumin to creatinine ratio was significantly elevated in urine samples obtained from GPR110 KO mice, indicating glomerular filtration dysfunction. The change in protein expression of key proteins including VEGFA is associated with the abnormal renal phenotype of albumin urea in GPR110 KO mice. In addition to the central nervous system phenotype such as learning and memory deficit and BBB dysfunction, our study revealed a new renal phenotype associated with lack of GPR110 signaling. " Authors & Affiliations "Laboratory of Molecular Signaling, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, USA" About Hee-Yong Kim "Senior Investigator and Chief of the Laboratory of Molecular Signaling at NIAAA, NIH" Hee-Yong Kim on the web NIH The Adhesion GPCR Cupidon Regulates Mating In The Closest Relatives Of Animals Alain Garcia De Las Bayonas Abstract "All animals develop through the recognition, adhesion, and fusion of a differentiated sperm and egg. Although fundamental, the evolution of gametogenesis and fertilization in animals is poorly understood. Recently, evidence for sex has been described in choanoflagellates, the closest living relatives of animals. Under nutrient depletion, the model choanoflagellate Salpingoeca rosetta forms distinct cell types that aggregate, fuse, and undergo meiotic recombination. Additionally, the bacterium Vibrio fischeri also induces mating in S. rosetta cultures, suggesting that multiple environmental cues can trigger sex. Importantly, the signaling pathways underlying sexual reproduction in these different contexts have not been investigated. In this study, we report the discovery of an adhesion GPCR, named Cupidon, that regulates the switch from vegetative growth to sexual reproduction in S. rosetta. We found that the knock-out of cupidon induces a gain in cell adhesion and cell fusion, resembling the mating behavior of wild-type cells under nutrient depletion. Cupidon mutants, similar to starved wild-type cells, upregulate various extracellular matrix-related genes, including teneurins and metalloproteases. Finally, we showed that nutrient availability controls the dissociation of the N-terminal fragment in Cupidon. Together, our results suggest that Cupidon prevents sexual reproduction in S. rosetta under high nutrient availability, by inhibiting genes involved in gamete recognition. " Authors & Affiliations "King Nicole, Howard Hughes Medical Institute and Department of Molecular and Cell Biology, University of California Berkeley" About Alain Garcia De Las Bayonas "Hi everyone! I am currently finishing my postoc in the laboratory of Pr Nicole King at UC Berkeley where I am studying the evolution of GPCR families in choanoflagellates, the sister group of animals. I have a particular interest in understanding the premetazoan function of adhesion GPCRs." Alain Garcia De Las Bayonas on the web King Lab Critical role for CD97/ADGRE5 in the induction of allergic airway inflammation Gabriela Aust Abstract Only available for AGPCR 24 Attendees Authors & Affiliations Coming Soon About Gabriela Aust Coming Soon Gabriela Aust on the web Coming Soon < Previous Session Next Session >

Home → Flash News → What are your thoughts on β2AR? Listen to Ep.163 of the @DrGPCR Podcast, where @DVeprintsev shares his thoughts and experiences about working with GPCRs, tips on framing your research correctly, and other insightful topics. Don’t miss out! ✳️https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #GPCRs #SciencePodcast #DrugDiscovery #Biotech #DrGPCR Published on April 3, 2025 Category Dr. GPCR Podcast What are your thoughts on β2AR? Listen to Ep.163 of the @DrGPCR Podcast, where @DVeprintsev shares his thoughts and experiences about working with GPCRs, tips on framing your research correctly, and other insightful topics. Don’t miss out! ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #GPCRs #SciencePodcast #DrugDiscovery #Biotech #DrGPCR Previous Next Recent Articles

Home → Flash News → A well-updated profile opens doors to collaborations and exciting GPCR projects 🚀 Don’t miss out—update yours now! Published on December 4, 2024 Category Dr. GPCR Profiles A well-updated profile opens doors to collaborations and exciting GPCR projects 🚀 Don’t miss out—update yours now! ✳️ Go to https://www.ecosystem.drgpcr.com/account/my-account and meet all the fantastic scientists that are part of our community 😉 #gpcr #drgpcr Previous Next Recent Articles